Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT).

"Declarations Ethics approval and consent to participateThe INSPIRE (NCT02644369) and MET4-IO (NCT03686202) trials were investigator-initiated studies, approved by the Princess Margaret Cancer Centre Research Ethics Board (#18–5950 and 15–9828). All the patients signed informed consent for the participation in the INSPIRE or MET4-IO studies. Samples obtained from the participants were used for this correlative study without interfering with the primary objectives of the two clinical trials. Consent for publicationAll the authors approved the current version of the manuscript and agree with publication. Competing interestsThe following authors have conflicts of interest to declare:Anna Spreafico:Consultant for (Advisory Board): Merck (compensated), Bristol-Myers Squibb (compensated), Oncorus (compensated), Janssen (compensated), Medison & Immunocore (compensated);Grant/Research support from (Clinical Trials): Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology/Johnson & Johnson, Roche, Regeneron, Alkermes, Array Biopharma/Pfizer, GSK, NuBiyota, Oncorus, Treadwell, Amgen.Lillian L. Siu:Consultant for (Advisory Board): Merck, Pfizer, AstraZeneca, Roche, GlaxoSmithKline, Voronoi, Arvinas, Tessa, Navire, Relay, Rubius, Daiichi Sanyko, Coherus, Marengo, InteRNA, Tubulis, LTZ Therapeutics, NGM Biotherapeutics.Stock ownership: Agios (spouse);Leadership position: Treadwell Therapeutics (spouse);Grant/Research support from (Clinical Trials): Novartis, Bristol-Myers Squibb, Pfizer, Boerhinger-Ingelheim, GlaxoSmithKline, Roche/Genentech, AstraZeneca, Merck, Celgene, Astellas, Bayer, Abbvie, Amgen, Symphogen, Shattucks, BionTech, 23Me, EMD Serono.Pavlina Spilopoulou:Honorarium: Pfizer. Competing interests The following authors have conflicts of interest to declare: Anna Spreafico: Consultant for (Advisory Board): Merck (compensated), Bristol-Myers Squibb (compensated), Oncorus (compensated), Janssen (compensated), Medison & Immunocore (compensated); Grant/Research support from (Clinical Trials): Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology/Johnson & Johnson, Roche, Regeneron, Alkermes, Array Biopharma/Pfizer, GSK, NuBiyota, Oncorus, Treadwell, Amgen. Lillian L. Siu: Consultant for (Advisory Board): Merck, Pfizer, AstraZeneca, Roche, GlaxoSmithKline, Voronoi, Arvinas, Tessa, Navire, Relay, Rubius, Daiichi Sanyko, Coherus, Marengo, InteRNA, Tubulis, LTZ Therapeutics, NGM Biotherapeutics. Stock ownership: Agios (spouse); Leadership position: Treadwell Therapeutics (spouse); Grant/Research support from (Clinical Trials): Novartis, Bristol-Myers Squibb, Pfizer, Boerhinger-Ingelheim, GlaxoSmithKline, Roche/Genentech, AstraZeneca, Merck, Celgene, Astellas, Bayer, Abbvie, Amgen, Symphogen, Shattucks, BionTech, 23Me, EMD Serono. Pavlina Spilopoulou: Honorarium: Pfizer."

"Funding This study was supported by Dr Spreafico's research funding and Dr. Genta's Novartis Young Canadian Investigator Award. Study drugs for the INSPIRE and MET4-IO studies were kindly provided by Merck and NuBiyota."